A systematic review of the efficacy of 18F-FDG PET in unknown primary tumors

Current Medical Imaging Reviews

Volumn 2, Issue 2, 2006, Pages 215-225

  Delgado Bolton, Roberto C ^a   Carreras, José L ^a,b   Pérez Castejón, Ma Jesús ^a  

^a Instituto PET Focuscan   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Carcinoma of unknown primary; Detection; FDG PET; Impact on management; Patient outcome; Unknown primary tumor

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

BRAIN METASTASIS; CANCER DIAGNOSIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG EFFICACY; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; LYMPH NODE METASTASIS; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; META ANALYSIS; OUTCOMES RESEARCH; PATIENT CARE; PERFORMANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW;

EID: 33745817076     PISSN: 15734056     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340506776930601     Document Type: Review

References (29)

1. Daugaard G. Unknown primary tumors. Cancer Treatment Rev 1994; 20: 119-147.
2. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 1995; 13: 2094-2103.
3. 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med 2003; 44: 1301-1314.
4. Rege S, Maass A, Chaiken L, et al. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer 1994; 73: 3047-3058.
5. Lassen U, Daugaard G, Eigtved A, Damgaard K, Friberg L. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). Eur J Cancer 1999; 35: 1076-1082.
6. Lonneux M, Reffad AM. Metastases from unknown primary tumor: PET-FDG as initial diagnostic procedure? Clin Positron Imaging 2000; 3: 137-141.
7. Bohuslavizki KH, Klutmann S, Kröger S, et al. FDG PET detection of unknown primary tumors. J Nucl Med 2000; 41: 816-822.
8. Schipper JH, Schrader M, Arweiler D, Muller S, Sciuk J. Positron emission tomography for primary tumor detection in lymph node metastases with unknown primary tumor. HNO 1996; 44: 254-257.
9. Kole AC, Nieweg OE, Pruim J, et al. Detection of unknown primary tumors using positron emission tomography. Cancer 1998; 82: 1160-1166.
10. Shinohara M, Tomita M, Ohira S, Nishimura A. Evaluation of 18F-FDG positron emission tomography (PET) in the detection of unknown primary tumors. Hokkaido Igaku Zasshi 1999; 74: 249-256.
11. Hanasono MM, Kunda LD, Segall GM, Ku GH, Terris DJ. Uses and limitations of FDG positron emission tomography in patients with head and neck cancer. Laryngoscope 1999; 109: 880-885.
12. Greven KM, Keyes JW Jr, Williams DW III, McGuirt WF, Joyce WT III. Occult primary tumors of the head and neck: lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose. Cancer 1999; 86: 114-118.
13. Safa AA, Tran LM, Rege S, et al. The role of positron emission tomography in occult primary head and neck cancers. Cancer J Sci Am 1999; 5: 214-218.
14. Gupta NC, Nicholson P, Bloomfield SM. FDG-PET in the staging work-up of patients with suspected intracranial metastatic tumors. Ann Surg 1999; 230: 202-206.
15. Aassar OS, Fischbein NJ, Caputo GR, et al. Metastatic head and neck cancer: Role and usefulness of FDG PET in locating occult primary tumors. Radiology 1999; 210: 177-181.
16. 18F-FDG whole body positron emission tomography (PET) in the detection of unknown primary tumors [abstract]. Clin Positron Imaging 2000; 3: 160.
17. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head Neck Surg 2000; 123: 294-301.
18. Cheng KC, Yeung HWD, Macapinlac H, Larson SM. Detection of occult primary tumors in patients presenting with cervical lymph node metastases by 18F-FDG PET [abstract]. Eur J Nucl Med 2000; 27: 902.
19. Eigtved A, Johansen J, Buchwald C, Theilgaard SA, Hansen HS. Implications of FDG-PET on treatment management of patients with cervical lymphnode metastases from an unknown primary tumor [abstract]. J Nucl Med 2001; 42 (Suppl): 80P.
20. Rades D, Kühnel G, Wildfang I, Börner AR, Schmoll HJ, Knapp W. Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management. Ann Oncol 2001; 12: 1605-1609.
21. 18F-FDG PET in patients with suspected metastatic brain tumors. J Nucl Med 2002; 43: 1432-1437.
22. Stoeckli SJ, Mosna-Firlejczyk K, Goerres GW. Lymph node metastasis of squamous cell carcinoma from an unknown primary: impact of positron emission tomography. Eur J Nucl Med Mol Imaging 2003; 30: 411-416.
23. 18F-FDG PET in unknown primary tumors [abstract]. Eur J Nucl Med Mol Imaging 2004; 31: S232-233.
24. Counsell C. Formulating questions and locating primary studies for inclusion in systematic reviews. Ann Intern Med 1997; 127: 380-387.
25. Grégoire G, Derderian F, Le Lorier J. Selecting the language of the publications included in a meta-analysis: is there a Tower of Babel bias? J Clin Epidemiol 1995; 48: 159-163.
26. Scherer RW, Dickersin K, Langenberg P. Full publication of results initially presented in abstracts: a meta-analysis. JAMA 1994; 272: 158-162.
27. Visvikis D, Ell PJ. Impact of technology on the utilisation of positron emission tomography in lymphoma: current and future perspectives. Eur J Nucl Med Mol Imaging 2003; 30 (Suppl. 1): S106-S116.
28. Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Making 1991; 11: 88-94.
29. 18F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med 2001; 42: 1605-1613.